<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704856</url>
  </required_header>
  <id_info>
    <org_study_id>2020.253 NL72539.029.20</org_study_id>
    <nct_id>NCT04704856</nct_id>
  </id_info>
  <brief_title>Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor</brief_title>
  <acronym>SPRINT</acronym>
  <official_title>Supervised Exercise to Promote Infiltration of NK-cells Into the Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      'Supervised exercise to PRomote Infiltration of NK-cells into the Tumor? The objective of&#xD;
      this feasibility study is to 1) study trial feasibility in terms of patient enrollment and&#xD;
      the percentage of tumor biopsies that can be examined successfully, and 2) generate&#xD;
      preliminary data on the potential effects of exercise on immune function assessed in the&#xD;
      tumor and in blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter randomized controlled feasibility trial, in which 20 women with breast&#xD;
      cancer scheduled for neoadjuvant 2 or 3 weekly AC-T(H) chemotherapy will be randomized into a&#xD;
      combined aerobic and resistance exercise intervention group or a usual care (no exercise)&#xD;
      control group, during the first 6 weeks (2 or 3 cycles) of chemotherapy. Patients from the&#xD;
      control group will receive care as usual and are requested to maintain their usual daily&#xD;
      physical activities. In order to limit contamination (increase of exercise in the control&#xD;
      group), non-participation and prevent dropout, the control group will be offered the same&#xD;
      6-week exercise intervention after the tumor biopsy has been taken after 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 6, 2021</start_date>
  <completion_date type="Anticipated">November 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participatient Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of patient actually enrolled in the study of all patients who will be screened</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful Examined Biopsies Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of tumor biopsies that can be examined successfully</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Generate preliminary data</measure>
    <time_frame>6 weeks</time_frame>
    <description>on the potential effects of exercise on immune function (Tumor tissue will be investigated by immunohistochemistry (IHC) to assess immune cell infiltration into the tumor with a specific focus on NK-cell frequency and phenotype) assessed in the tumor and in blood.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Interventiongroup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventiongroup, undergo supervised exercise for the first 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlgroup</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Controlgroup, do not undergo supervised exercise for the first 6 weeks (possibility to undergo supervised exercise after 6 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supervised exercise</intervention_name>
    <description>Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.</description>
    <arm_group_label>Interventiongroup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stage I-III breast cancer&#xD;
&#xD;
          -  scheduled for neoadjuvant chemotherapy with 2 or 3-weekly Adriamycin/Cyclofosfamide,&#xD;
             followed by Paclitaxel weekly +/- trastuzumab&#xD;
&#xD;
          -  willing to undergo an additional ultrasound guided biopsy&#xD;
&#xD;
          -  ECOG-performance score ≤ 2 (able to perform basic activities of daily living such as&#xD;
             walking or biking)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  addition of immuno- or targeted therapy at start of neoadjuvant chemotherapy&#xD;
&#xD;
          -  currently participating in structured vigorous aerobic exercise and/or resistance&#xD;
             exercise&#xD;
&#xD;
        (≥2 days per week).&#xD;
&#xD;
          -  cognitive disorder or severe emotional instability&#xD;
&#xD;
          -  presence of other disabling co-morbidity that might hamper physical exercise e.g.&#xD;
             heart failure (NYHA classes 3 and 4), chronic obstructive pulmonary disease (COPD,&#xD;
             gold 3 and 4), orthopaedic conditions and neurological disorders (e.g., hernia,&#xD;
             paresis, amputation, active rheumatoid arthritis);&#xD;
&#xD;
          -  immunosuppressive medication (e.g. corticosteroids (other than used as part of&#xD;
             standard chemotherapy premedication protocol), cyclosporine)&#xD;
&#xD;
          -  immunodeficiency (primary or secondary)&#xD;
&#xD;
          -  impossibility to perform an ultrasound-guided biopsy of the tumor&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Stage I-III breastcancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans van der Vliet, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurien Buffart, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marieke ten Tusscher, MSc.</last_name>
    <role>Study Chair</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne van der Velde, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marieke ten Tusscher, MSc.</last_name>
    <phone>020 444 1050</phone>
    <email>m.r.tentusscher@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurien Buffart, PhD</last_name>
    <phone>024 3613674</phone>
    <email>laurien.buffart@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <state>Flevoziekenhuis</state>
        <zip>1315RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sadaf Kaashoek, Trialcoordinator</last_name>
      <phone>036 8689491</phone>
      <email>studiesoncohema@flevoziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>S. Havenith, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marieke ten Tusscher, MSc</last_name>
      <phone>020 444 1050</phone>
      <email>m.r.tentusscher@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Laurien Buffart, PhD</last_name>
      <phone>024 3613674</phone>
      <email>laurien.buffart@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Hans van der Vliet, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurien Buffart, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Hans J. van der Vliet, MD, PhD</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Stage I-III breastcancer</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Exercise</keyword>
  <keyword>NK-cells</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>POLARIS study (PROSPERO 2013 CRD42013003805)</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT04704856/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

